Skip to main content
NanoRepro AG logo

NanoRepro AG — Investor Relations & Filings

Ticker · NN6 ISIN · DE0006577109 LEI · 3912008FCA63AGIMEV74 F Manufacturing
Open in API
Filings indexed 414 across all filing types
Latest filing 2018-01-31 Audit Report / Informat…
Country DE Germany
Listing F NN6

About NanoRepro AG

https://www.nanorepro.com/en/

NanoRepro AG is a company specializing in the development, manufacturing, and distribution of CE-marked rapid diagnostic tests (self-tests) and food supplements. The products are designed for both home and professional use. The company's portfolio covers various health areas, including family planning, preventive healthcare, disease detection, food intolerances, allergies, and infectious diseases. The primary goal is to provide accuracy in self-diagnostics for rapid disease detection and health monitoring.

Recent filings

Filing Released Lang Actions
Datum:31.01.2018
Audit Report / Information Classification · 98% confidence The document is a 'Jahresabschluss' (Annual Financial Statement) for Oehmichen Optik AG for the fiscal year 2016. It contains a balance sheet (Bilanz) and notes (Anhang) detailing accounting policies, valuation methods, and financial disclosures. While it is a component of an annual report, it is presented as the formal financial statement filing itself rather than a summary or an announcement. In the context of the provided categories, this constitutes the core financial reporting document. FY 2016
2018-01-31 German
Datum:18.01.2018
Annual Report Classification · 100% confidence The document is a 'Jahresabschluss' (Annual Financial Statement) for NanoRepro AG for the fiscal year 2016. It contains a balance sheet (Bilanz), detailed notes (Anhang), and disclosures required by the German Commercial Code (HGB) and Stock Corporation Act (AktG). As it provides comprehensive financial statements for a full fiscal year, it is classified as an Annual Report (10-K equivalent in this context). FY 2016
2018-01-18 German
Nanorepro AG gewinnt dm als Handelspartner
Regulatory Filings Classification · 100% confidence The document is a short news release dated December 18, 2017, announcing a new commercial partnership between Nanorepro AG and the retailer dm. It highlights the addition of four medical rapid tests to dm's product line starting in April and uses this event to reaffirm the company's 2018 revenue and EBITDA guidance. The text is structured as a press release, mentioning 'DGAP-News' and 'Corporate News/Finanznachricht'. Since it is an announcement about business developments and financial outlook rather than a comprehensive periodic financial report (like 10-K or IR), a capital event (CAP), or a formal earnings release (ER), it best fits the general category for regulatory announcements or news releases that don't fit elsewhere. Given the content is a significant business update/partnership announcement, it is most appropriately classified as a general Regulatory Filing (RNS) as it is distributed via a news service (DGAP) and doesn't match the more specific categories like M&A (TAR) or Capital Change (CAP). It is too detailed for a simple Report Publication Announcement (RPA) as it contains substantive news, not just a notice about a report release.
2017-12-18 German
Nanorepro AG mit hoherem Umsatz und besserem Ergebnis
Earnings Release Classification · 100% confidence The document is a news release dated December 5, 2017, titled "Nanorepro AG mit höherem Umsatz und besserem Ergebnis" (Nanorepro AG with higher revenue and better results). It explicitly details key financial figures for the first three quarters (Q1-Q3) of the current fiscal year (revenue increase, EBITDA loss reduction) and provides forecasts for the full year 2017 and 2018. This structure—presenting key period results and forward-looking guidance immediately following the period close—is characteristic of an Earnings Release (ER), which provides the initial announcement of periodical financial results (key highlights only), rather than the comprehensive Interim Report (IR) or the full Annual Report (10-K). The document is short and focuses on highlights, fitting the ER definition better than a full MDA or IR. 9M 2017
2017-12-05 German
Nanorepro AG passt Prognose fur 2017 an
Regulatory Filings Classification · 95% confidence The document is an 'Ad-hoc' announcement dated December 4, 2017, titled 'Nanorepro AG passt Prognose für 2017 an' (Nanorepro AG adjusts forecast for 2017). It explicitly states it is an 'Insiderinformation gemäß Artikel 17 MAR' (Inside Information according to Article 17 MAR). The content details revisions to expected revenue and EBITDA for 2017 and provides a new forecast for 2018. This type of announcement, which modifies financial outlook or provides material non-public information outside of scheduled earnings reports, is best classified as a general Regulatory Filing (RNS) or potentially an Earnings Release (ER) if it were a scheduled update. However, since it is an unscheduled, ad-hoc disclosure of a forecast change under MAR regulations, and it doesn't fit the specific definitions for ER (initial announcement of results), IR (comprehensive interim report), or 10-K (annual report), the most appropriate general regulatory category is RNS. Given the short length and the nature of an ad-hoc disclosure, RNS is the best fit among the provided options for a mandatory, unscheduled regulatory disclosure that isn't a specific report type.
2017-12-04 German
DGAP-DD: NanoRepro AG english
Director's Dealing Classification · 100% confidence The document is explicitly titled 'Directors’ Dealings' and contains sections detailing 'Details of the person discharging managerial responsibilities' (Dr. Olaf Stiller, Member of the administrative or supervisory body) and 'Details of the transaction(s)' involving the issuer's shares. This content directly corresponds to the definition of Director's Dealing reports, which are classified under the code DIRS.
2017-11-14 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.